Sonrotoclax
drugOn this page
Also known as Bgb 11417Bgb-11417BGB11417US11420968Example F43
Summary
Sonrotoclax (CHEMBL5314951) is a phase-3 clinical-stage small molecule targeting BCL2; indicated across 6 conditions including b-cell chronic lymphocytic leukemia and neoplasm.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Targets: 1 (BCL2)
- Indications: 6 conditions
- Clinical trials: 31
- Chemistry: 890.1 Da · C49H59N7O7S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5314951 |
| Name | Sonrotoclax |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 149553242 |
| Molecular formula | C49H59N7O7S |
| Molecular weight | 890.1 |
| InChIKey | ZQTKOYMWCCSKON-HCWAPQBJSA-N |
SMILES: CC(C)C1=CC=CC=C1[C@@H]2CCCN2C3CC4(C3)CCN(CC4)C5=CC(=C(C=C5)C(=O)NS(=O)(=O)C6=CC(=C(C=C6)NCC7CCC(CC7)(C)O)[N+](=O)[O-])OC8=CN=C9C(=C8)C=CN9
IUPAC name: N-[4-[(4-hydroxy-4-methylcyclohexyl)methylamino]-3-nitrophenyl]sulfonyl-4-[2-[(2S)-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
Also known as: Bgb 11417, Bgb-11417, BGB-11417, BGB11417, Sonrotoclax, SONROTOCLAX, US11420968, Example F43
Patent coverage: 3 distinct patent families (3 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| BCL2 | BCL2 apoptosis regulator | Antagonist | 10.72 | 3.3% | P10415 |
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Bcl-2-like protein 1, Apoptosis regulator Bcl-2.
Bioactivity
ChEMBL activities: 7 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| BCL2 | 10.82 | IC50 | 0.01 | nM | CHEMBL_ACT_28777493 |
| BCL2 | 10.72 | IC50 | 0.02 | nM | CHEMBL_ACT_25860892 |
| BCL2 | 9.62 | Kd | 0.24 | nM | CHEMBL_ACT_25861232 |
| BCL2 | 9.47 | IC50 | 0.34 | nM | CHEMBL_ACT_25861170 |
| BCL2 | 9.38 | IC50 | 0.42 | nM | CHEMBL_ACT_28777121 |
| BCL2L1 | 7.75 | IC50 | 18 | nM | CHEMBL_ACT_28777496 |
| BCL2L1 | 7.55 | IC50 | 28 | nM | CHEMBL_ACT_25860977 |
Target pathways
Aggregated over 1 target gene(s): BCL2.
Top Reactome pathways
30 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Apoptosis | 1 | BCL2 |
| Intrinsic Pathway for Apoptosis | 1 | BCL2 |
| Activation of BAD and translocation to mitochondria | 1 | BCL2 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | 1 | BCL2 |
| Activation of BH3-only proteins | 1 | BCL2 |
| Developmental Biology | 1 | BCL2 |
| Cytokine Signaling in Immune system | 1 | BCL2 |
| Signal Transduction | 1 | BCL2 |
| Innate Immune System | 1 | BCL2 |
| Immune System | 1 | BCL2 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 1 | BCL2 |
| Cellular responses to stress | 1 | BCL2 |
| Signaling by Interleukins | 1 | BCL2 |
| Programmed Cell Death | 1 | BCL2 |
| Inflammasomes | 1 | BCL2 |
| Interleukin-4 and Interleukin-13 signaling | 1 | BCL2 |
| The NLRP1 inflammasome | 1 | BCL2 |
| ESR-mediated signaling | 1 | BCL2 |
| Cellular responses to stimuli | 1 | BCL2 |
| Signaling by Nuclear Receptors | 1 | BCL2 |
| Extra-nuclear estrogen signaling | 1 | BCL2 |
| Estrogen-dependent gene expression | 1 | BCL2 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 1 | BCL2 |
| Cellular response to chemical stress | 1 | BCL2 |
| MITF-M-regulated melanocyte development | 1 | BCL2 |
| KEAP1-NFE2L2 pathway | 1 | BCL2 |
| Nuclear events mediated by NFE2L2 | 1 | BCL2 |
| NFE2L2 regulating tumorigenic genes | 1 | BCL2 |
| Regulation of MITF-M-dependent genes involved in apoptosis | 1 | BCL2 |
| MITF-M-dependent gene expression | 1 | BCL2 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| G1/S transition of mitotic cell cycle | 1 |
| protein polyubiquitination | 1 |
| ossification | 1 |
| ovarian follicle development | 1 |
| metanephros development | 1 |
| branching involved in ureteric bud morphogenesis | 1 |
| behavioral fear response | 1 |
| B cell homeostasis | 1 |
| B cell apoptotic process | 1 |
| release of cytochrome c from mitochondria | 1 |
| regulation of cell-matrix adhesion | 1 |
| lymphoid progenitor cell differentiation | 1 |
| B cell lineage commitment | 1 |
| negative regulation of B cell apoptotic process | 1 |
| response to ischemia | 1 |
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| B-cell chronic lymphocytic leukemia | 3 | MONDO:0004948 | EFO:0000095 |
| neoplasm | 2 | MONDO:0005070 | EFO:0000616 |
| mantle cell lymphoma | 2 | MONDO:0018876 | EFO:1001469 |
| Waldenstrom macroglobulinemia | 2 | MONDO:0100280 | EFO:0009441 |
| plasma cell myeloma | 1 | MONDO:0009693 | EFO:0001378 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 31.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 15 |
| PHASE1 | 6 |
| PHASE3 | 5 |
| PHASE1/PHASE2 | 5 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06073821 | PHASE3 | ACTIVE_NOT_RECRUITING | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) |
| NCT06742996 | PHASE3 | RECRUITING | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) |
| NCT06943872 | PHASE3 | RECRUITING | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) |
| NCT07277231 | PHASE3 | RECRUITING | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia |
| NCT07321652 | PHASE3 | NOT_YET_RECRUITING | Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL |
| NCT04271956 | PHASE2 | RECRUITING | Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation |
| NCT04771130 | PHASE1/PHASE2 | RECRUITING | A Study of BGB-11417 in Participants With Myeloid Malignancies |
| NCT04973605 | PHASE1/PHASE2 | RECRUITING | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma |
| NCT05471843 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma |
| NCT05479994 | PHASE2 | ACTIVE_NOT_RECRUITING | Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| NCT05952037 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia |
| NCT06367374 | PHASE2 | NOT_YET_RECRUITING | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL |
| NCT06463691 | PHASE2 | RECRUITING | Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients |
| NCT06497062 | PHASE2 | ACTIVE_NOT_RECRUITING | Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia |
| NCT06547866 | PHASE2 | NOT_YET_RECRUITING | Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia |
| NCT06634589 | PHASE1/PHASE2 | RECRUITING | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies |
| NCT06637501 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia |
| NCT06697184 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. |
| NCT06839053 | PHASE2 | RECRUITING | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma |
| NCT06849713 | PHASE2 | RECRUITING | Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL |
| NCT06854003 | PHASE2 | RECRUITING | BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma |
| NCT07335887 | PHASE2 | NOT_YET_RECRUITING | Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis |
| NCT07341191 | PHASE2 | RECRUITING | Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy |
| NCT07508995 | PHASE2 | NOT_YET_RECRUITING | A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) |
| NCT07548710 | PHASE2 | RECRUITING | Study of SA+X in the Treatment of Newly Diagnosed AML |
| NCT04277637 | PHASE1 | ACTIVE_NOT_RECRUITING | Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies |
| NCT04883957 | PHASE1 | ACTIVE_NOT_RECRUITING | Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies |
| NCT06859008 | PHASE1 | RECRUITING | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
| NCT07548255 | PHASE1 | NOT_YET_RECRUITING | The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL |
| NCT06543043 | PHASE1 | COMPLETED | A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers |
| NCT07141511 | PHASE1 | COMPLETED | A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
9 molecules share ≥1 primary target. Top 9 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| IXABEPILONE | ChEMBL | Phase 4 (approved) | BCL2 |
| VENETOCLAX | ChEMBL | Phase 4 (approved) | BCL2 |
| EPIGALOCATECHIN GALLATE | ChEMBL | Phase 3 | BCL2 |
| GOSSYPOL | ChEMBL | Phase 3 | BCL2 |
| NAVITOCLAX | ChEMBL | Phase 3 | BCL2 |
| OBATOCLAX | ChEMBL | Phase 3 | BCL2 |
| CHLORCYCLIZINE | ChEMBL | Phase 2 | BCL2 |
| FORMONONETIN | ChEMBL | Phase 2 | BCL2 |
| LACUTOCLAX | ChEMBL | Phase 2 | BCL2 |
Related Atlas pages
- Genes: BCL2
- Diseases: B-cell chronic lymphocytic leukemia
- Drugs: Ixabepilone, Venetoclax, Epigalocatechin Gallate, Gossypol, Navitoclax, Obatoclax